Introduction:

During viral infections, the body produces binding antibodies (n-NAbs) and neutralizing antibodies (NAbs). NAbs prevent viral infection of host cells. Since COVID-19's onset in 2020, vaccine research has focused on eliciting high NAb levels.

Objective:

To evaluate IgA, IgM, and IgG levels in Colombian healthcare workers and compare NAb test results from DIA.PRO and CPAS.

Method:

A cross-sectional study in Bucaramanga, Colombia, collected samples from healthcare workers in June-July and November 2021. Data was gathered via an online survey and blood samples. Antibody levels were measured with AESKULISA® kits, and neutralizing activity was assessed using DIA.PRO and cPass kits. Statistical analyses used Wilcoxon tests and Pearson correlation.

Results:

Eighty participants were initially assessed, with forty-seven re-evaluated. Most were women who had received the BioNTech-Pfizer vaccine. Antibody levels declined over time; IgA and IgM were lower in the second sampling, while IgG remained high. Prior COVID-19 infection correlated with higher antibody levels. DIA.PRO and CPAS tests showed strong agreement, with excellent neutralizing reactivity in most participants.

Conclusion:

Neutralizing antibody levels against SARS-CoV-2 decrease but remain effective in most healthcare workers, supporting BNT162b2 vaccine efficacy. Further research is needed on emerging variants and neutralizing antibodies in COVID-19 management.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )